As of January, 2022, the U.S. Centers for Disease Control and Prevention (CDC) recommends the use of the vaccine Shingrix to prevent shingles and its complications in adults 19 years and older whose immune systems are weakened in addition to those adults 50 years and older whose immune systems are not compromised. Shingrix was approved for this additional use in July, 2021.
The CDC recommends two doses of vaccine with the second dose given 2-6 months after the first. However for people who are immunocompromised, the second dose can be given 1-2 months after the first.
Immunocompromised people are defined as those who are immunodeficient or immunosuppressed as a result of either disease or side effects of a therapy. Patients with autoimmune and inflammatory conditions are included in the population defined by the CDC as immunocompromised.